By Ana Espino | Published on April 2, 2026 | 2 min read
Kidney
dysfunction, whether acute (AKI) or chronic (CKD), represents a major public
health issue. It is characterized by the progressive accumulation of
uremic
solutes and
persistent systemic inflammation—two closely linked mechanisms
involved in disease progression and the development of complications,
particularly cardiovascular ones.
Current
diagnostic tools, especially serum creatinine, remain insufficient to capture
the complexity of the underlying mechanisms. They fail to fully integrate the
interplay between inflammation, apoptosis, and cellular dysfunction, which are
central to renal pathophysiology.
In this
context,
soluble Fas (sFas)—the circulating form of the CD95 receptor involved
in apoptosis regulation—has gained increasing attention. Its potential role in
modulating inflammatory responses and in the progression of kidney damage makes
it a
promising biomarker candidate.
However, its
exact role in kidney dysfunction remains to be clarified. This study, published
in 2026 in the Brazilian Journal of Nephrology, aimed to analyze the
association between sFas, inflammatory markers, and renal function, in order to
assess its clinical relevance and potential as an integrated biomarker.
Does sFas
truly reflect renal severity?
The authors
conducted a systematic review and meta-analysis including 24 observational
studies (13 cohort and 11 cross-sectional), with quantitative synthesis focused
on 8 comparable cohorts.
A total of
1,449 patients with kidney dysfunction were included. The data show a clear
elevation of biomarkers in these patients, with mean creatinine levels of 2.8
mg/dL compared to 0.7 mg/dL in individuals without kidney disease.
Consistently, levels of sFas (8,635 vs 3,206 pg/mL) and IL-6 (193.4 vs 29.7
pg/mL) were significantly higher, reflecting an enhanced inflammatory state.
Quantitative
analysis confirmed this trend. The meta-analysis demonstrated a
significant
association between sFas levels and kidney dysfunction, with
moderate
heterogeneity, as illustrated in the
forest plot.
Beyond this
association, the results revealed
consistent positive correlations between
sFas, creatinine, and IL-6, highlighting the close interplay between impaired
renal function and systemic inflammation. A significant relationship was also
observed between sFas and C-reactive protein (CRP) (OR = 0.72; p = 0.001),
although based on a limited number of studies.
Overall, these
findings suggest that sFas may act as a true biological reflection of kidney dysfunction,
integrating both uremic retention and inflammatory activation mechanisms.
A promising
biomarker, still to be confirmed
Kidney
dysfunction is a complex condition characterized by
chronic inflammation and
progressive accumulation of
uremic toxins, with interactions that remain
incompletely understood. In this context, identifying
reliable and integrative
biomarkers is a major clinical challenge.
This study
aimed to evaluate the role of
sFas within these mechanisms. The results show
that elevated
sFas levels are significantly associated with kidney dysfunction
and inflammatory markers, suggesting its involvement in underlying
pathophysiological processes.
However,
interpretation of these findings is limited by
methodological heterogeneity, a
limited number of studies for certain biomarkers—particularly IL-6—and the
absence of analyses stratified by renal phenotypes.
Although
further large-scale prospective studies are needed, these findings highlight
the potential of
sFas as an integrated biomarker at the intersection of
inflammation and uremic retention. In the future, its use could contribute to
more
refined risk stratification and improved therapeutic strategies in
nephrology.
Read next: Kidneys under pressure?
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
